Edaravone: A new hope for patients with amyotrophic lateral sclerosis
Although the exact pathophysiology of amyotrophic lateral sclerosis (ALS) remains unclear, oxidative stress is known to play a pivotal role. There is no cure for ALS, but there are two drugs available to slow the progression of the disease. Till recently, riluzole, a glutamatergic neurotransmission...
Main Authors: | Shivangi Garg, Dinesh Chaudhari, Pushpendra Nath Renjen, Anjali Mishra, Abhas Kumar, Rajendra Pradhan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
Series: | Apollo Medicine |
Subjects: | |
Online Access: | http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2019;volume=16;issue=3;spage=157;epage=160;aulast=Garg |
Similar Items
-
A New Treatment Option for Amyotrophic Lateral Sclerosis: Edaravone
by: Erdi Şahin
Published: (2018-03-01) -
Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study
by: Jin-Mo Park, et al.
Published: (2022-07-01) -
Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan
by: Hideki Houzen, et al.
Published: (2021-07-01) -
Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection
by: Sun Joo Cha, et al.
Published: (2022-01-01) -
Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone
by: Hee Jo Han, et al.
Published: (2022-12-01)